(RTTNews) - Shares of Ventyx Biosciences Inc. (VTYX) skyrocketed over 83% in after-hours trading on Wednesday after the company announced positive results from its Phase 2 study of VTX3232, an oral, ...
Ventyx Biosciences, Inc. surged ~90% after positive Phase 2 results for VTX3232 in obesity and cardiovascular risk factors, restoring optimism in its pipeline. VTYX3232 showed significant reductions ...
Additive effects were observed for VTX3232 in combination with the GLP-1 receptor agonist semaglutide across key endpoints compared to semaglutide or VTX3232 alone SAN DIEGO, June 05, 2024 (GLOBE ...
Ventyx Biosciences, Inc. is focusing on advancing VTX3232 for obesity and Parkinson's, with early but promising preclinical results in obesity. The drug VTX3232 has shown potential in preclinical ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback